Abstract
Heart failure remains the main cause of death in children with heart disease. In USA and Europe hospital mortality of children with heart failure is about 7% of children, nearly twice as high as in adults. In this review a group of authors report about their experience with beta-blockers in childhood heart failure. Most of them start to treat children with severe heart failure at a time - 20 years ago - when beta blockers seem to be contraindicated in this situation. The physicians and their patients and/or parents all are aware of the risk of this decision. However, unproven medical therapies for heart failure are the most important therapeutical dilemma in pediatric cardiology. The authors carefully observed a highly selected group of patients with the highest risk to die and had the patience to wait for the longtime follow up. Today - based upon this experience –we know that beta blockers are safe and may save the lives of many children with heart disease all over the world. Together with young colleagues who enthusiastically support this idea the authors now intend to break down the “wall of ignorance” for this promising therapy in pediatric cardiology.
Keywords: Beta-blockers, childhood, duchenne, heart failure, hypertrophic cardiomyopathy, sudden death.
Reviews on Recent Clinical Trials
Title:Editorial (Thematic Issue: The Long Way to a Successful Medical Therapy of Heart Failure with Beta-blockers in Children with Heart Disease)
Volume: 9 Issue: 2
Author(s): Reiner Buchhorn and Robert D. Ross
Affiliation:
Keywords: Beta-blockers, childhood, duchenne, heart failure, hypertrophic cardiomyopathy, sudden death.
Abstract: Heart failure remains the main cause of death in children with heart disease. In USA and Europe hospital mortality of children with heart failure is about 7% of children, nearly twice as high as in adults. In this review a group of authors report about their experience with beta-blockers in childhood heart failure. Most of them start to treat children with severe heart failure at a time - 20 years ago - when beta blockers seem to be contraindicated in this situation. The physicians and their patients and/or parents all are aware of the risk of this decision. However, unproven medical therapies for heart failure are the most important therapeutical dilemma in pediatric cardiology. The authors carefully observed a highly selected group of patients with the highest risk to die and had the patience to wait for the longtime follow up. Today - based upon this experience –we know that beta blockers are safe and may save the lives of many children with heart disease all over the world. Together with young colleagues who enthusiastically support this idea the authors now intend to break down the “wall of ignorance” for this promising therapy in pediatric cardiology.
Export Options
About this article
Cite this article as:
Buchhorn Reiner and Ross D. Robert, Editorial (Thematic Issue: The Long Way to a Successful Medical Therapy of Heart Failure with Beta-blockers in Children with Heart Disease), Reviews on Recent Clinical Trials 2014; 9 (2) . https://dx.doi.org/10.2174/157488710902141009103818
DOI https://dx.doi.org/10.2174/157488710902141009103818 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Transcription Factors in the Formation of an Arrhythmogenic Substrate in Congestive Human Heart Failure
Current Medicinal Chemistry Newer Insights in Personalized and Evidence Based Medicine- the Role of MicroRNAs
Current Pharmacogenomics and Personalized Medicine Epidemiology of Gout: Perspectives from the Past
Current Rheumatology Reviews Anti-Inflammatory and Pro-Resolving Effects of N-3 PUFA in Cancers: Structures and Mechanisms
Current Topics in Medicinal Chemistry Folate and Homocysteine Metabolism: Therapeutic Targets in Cardiovascular and Neurodegenerative Disorders
Current Medicinal Chemistry Combining “Omics” Strategies to Analyze the Biotechnological Potential of Complex Microbial Environments
Current Protein & Peptide Science Overview of Therapeutic Potential of Rapamycin for Coronary Artery Diseases in the Era of the Drug-Eluting Stent
Vascular Disease Prevention (Discontinued) Novel Non-Steroidal Anti-Inflammatory Drugs: What we have Learned from Animal Studies
Current Drug Targets - Inflammation & Allergy Niemann-Pick C1-Like 1 (NPC1L1) Inhibition and Cardiovascular Diseases
Current Medicinal Chemistry Serum Collagen Markers and Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Receptor-Binding and Pharmacokinetic Properties of Dopaminergic Agonists
Current Topics in Medicinal Chemistry von Willebrand Factor, von Willebrand Factor-Cleaving Protease, and Shear Stress
Cardiovascular & Hematological Agents in Medicinal Chemistry Effects of PPARγ Ligands on Vascular Tone
Current Molecular Pharmacology Editorial (Thematic Issue: Is The Female Heart Exposed To Cardiovascular Disease?)
Current Medicinal Chemistry Subject Index to Volume 2
Current Vascular Pharmacology Morbidity and Mortality Associated with Pharmacotherapy. Evolution and Current Concept of Drug-Related Problems
Current Pharmaceutical Design Current Concepts on Prenatal Diagnosis and Management of Fetal Tachyarrythmias
Current Cardiology Reviews Sundowning Syndrome: A Possible Marker of Frailty in Alzheimer’s Disease?
CNS & Neurological Disorders - Drug Targets Polyphenols Effect on Circulating Lipids and Lipoproteins: From Biochemistry to Clinical Evidence
Current Pharmaceutical Design Impaired Renal Function and Biomarkers of Vascular Disease in Alzheimer’s Disease
Current Alzheimer Research